30 closest matches · ranked by relevance
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
Venous Thromboembolism
Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants
Superficial Thrombophlebitis · Upper Extremity Superficial Thrombophlebitis · Lower Extremity Superficial Thrombophlebitis
Primary: Thrombosis Progression and Venous Thromboembolism (VTE) — 4; 0; 0; 0 participants
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
Thrombosis
Primary: Total Number of Participants Who Completed the Study-Related Ultrasound (US) and Magnetic Resonance Imaging (MRI) With and Without Contrast — 133; 113; 113; 110…
Venous Thrombosis · Deep Vein Thrombosis
Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
Post Thrombotic Syndrome · Deep Vein Thrombosis · Venous Stasis Syndrome
Primary: Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms — 32 mirco coulombs (0 to 50)
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Thromboembolic Disease Recurrent · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Validation of the Wells DVT Clinical Decision Rule — 67; 186; 148; 4 Participants
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137